GlassScriptPhysician profile
Sandra K Force-Obrowski
NPI 1023034873
$15,383.27
in general payments reported to CMS, 2019-2025
41 companies · $2,120 in 2025
The $2,120 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $1,446 · 2021: $2,341 · 2022: $3,536 · 2023: $2,026 · 2024: $2,391 · 2025: $2,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,452 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,451.76 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,048.19 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,095.43 | 2019-2025 | |
| Lilly USA, LLC | $762.70 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $634.26 | 2019-2022 | |
| Axsome Therapeutics, INC. | $595.09 | 2023-2025 | Auvelity, Symbravo |
| Amgen INC. | $578.07 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $572.78 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.07 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $465.63 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $440.40 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $410.32 | 2019-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $395.53 | 2020-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $395.26 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $390.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $382.17 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Force-Obrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.